{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:21:00Z","timestamp":1758417660326,"version":"3.44.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jns.2021.117505","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T12:38:37Z","timestamp":1621600717000},"page":"117505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"427","author":[{"given":"Ahmed Taher","family":"Masoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Tarek","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey Nabil","family":"Edward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mohamed","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman Elshahat","family":"Naga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elfil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badrah S.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Perveen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam Md","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshak I.","family":"Bahbah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jns.2021.117505_bb0005","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/14737175.2016.1200973","article-title":"Chronic migraine treatment: from OnabotulinumtoxinA onwards","volume":"16","author":"Negro","year":"2016","journal-title":"Expert. Rev. Neurother."},{"issue":"6","key":"10.1016\/j.jns.2021.117505_bb0010","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpdd.345","article-title":"Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date","volume":"6","author":"Pellesi","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"5 Suppl","key":"10.1016\/j.jns.2021.117505_bb0015","first-page":"S3","article-title":"Tracing transformation: chronic migraine classification, progression, and epidemiology","volume":"72","author":"Lipton","year":"2009","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.jns.2021.117505_bb0020","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jns.2021.117505_bb0025","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","article-title":"The cost of headache disorders in Europe: the Eurolight project","volume":"19","author":"Linde","year":"2012","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2021.117505_bb0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s10194-018-0909-4","article-title":"Migraine and cluster headache \u2013 The common link","volume":"19","author":"Vollesen","year":"2018","journal-title":"J. Headache Pain."},{"issue":"2","key":"10.1016\/j.jns.2021.117505_bb0035","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol. Rev."},{"year":"2016","author":"Antonaci","series-title":"Recent Advances in Migraine Therapy","key":"10.1016\/j.jns.2021.117505_bb0040"},{"year":"2008","journal-title":"J. Compar. Neurol. - Wiley Online Library","key":"10.1016\/j.jns.2021.117505_bb0045"},{"issue":"8","key":"10.1016\/j.jns.2021.117505_bb0050","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/0333102412472072","article-title":"Pearls and pitfalls in neural CGRP immunohistochemistry","volume":"33","author":"Warfvinge","year":"2013","journal-title":"Cephalalgia."},{"issue":"1","key":"10.1016\/j.jns.2021.117505_bb0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","article-title":"Cgrp may play a causative role in migraine","volume":"22","author":"Lassen","year":"2002","journal-title":"Cephalalgia."},{"issue":"2","key":"10.1016\/j.jns.2021.117505_bb0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10194-011-0408-3","article-title":"Antidromic vasodilatation and the migraine mechanism","volume":"13","author":"Geppetti","year":"2012","journal-title":"J. Headache Pain."},{"issue":"10","key":"10.1016\/j.jns.2021.117505_bb0065","first-page":"1179","article-title":"Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura","volume":"30","author":"Hansen","year":"2019","journal-title":"PubMed - NCBI [Internet]"},{"key":"10.1016\/j.jns.2021.117505_bb0070","article-title":"NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet s","author":"Juhasz","year":"2019","journal-title":"PubMed - NCBI [Internet]"},{"issue":"9","key":"10.1016\/j.jns.2021.117505_bb0075","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.jns.2021.117505_bb0080","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jns.2021.117505_bb0085","series-title":"Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Vol. Version 5","first-page":"1","author":"Higgins","year":"2008"},{"key":"10.1016\/j.jns.2021.117505_bb0090","series-title":"Cochrane Handbook for: Systematic Reviews of Interventions","first-page":"3","article-title":"Cochrane handbook: Cochrane reviews: Ch 8: assessing risk of bias in included studies","author":"Green","year":"2011"},{"key":"10.1016\/j.jns.2021.117505_bb0095","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3389\/fphar.2019.00795","article-title":"Network Meta-analysis of calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jns.2021.117505_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/head.12499","article-title":"The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies","volume":"55","author":"Marmura","year":"2015","journal-title":"Headache: J. Head Face Pain."},{"issue":"2","key":"10.1016\/j.jns.2021.117505_bb0105","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1542\/peds.2004-2742","article-title":"Symptomatic treatment of migraine in children: a systematic review of medication trials","volume":"116","author":"Damen","year":"2005","journal-title":"PEDIATRICS."},{"issue":"S2","key":"10.1016\/j.jns.2021.117505_bb0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/head.13583","article-title":"Targeting CGRP for the prevention of migraine and cluster headache: a narrative review","volume":"59","author":"Yuan","year":"2019","journal-title":"Headache: J. Head Face Pain."},{"issue":"16","key":"10.1016\/j.jns.2021.117505_bb0115","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s40265-018-1002-7","article-title":"Galcanezumab: First Global Approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs."},{"issue":"12","key":"10.1016\/j.jns.2021.117505_bb0120","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.joca.2018.08.019","article-title":"CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial","volume":"26","author":"Jin","year":"2018","journal-title":"Osteoarthr. Cartil."},{"issue":"22","key":"10.1016\/j.jns.2021.117505_bb0125","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jns.2021.117505_bb0130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/WCO.0000000000000440","article-title":"Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine","volume":"30","author":"Ram\u00f3n","year":"2017","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2021.117505_bb0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","article-title":"Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination","volume":"20","author":"Raffaelli","year":"2019","journal-title":"J. Headache Pain."},{"issue":"5","key":"10.1016\/j.jns.2021.117505_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11916-019-0768-y","article-title":"CGRP antagonists for the treatment of chronic migraines: a comprehensive review","volume":"23","author":"Urits","year":"2019","journal-title":"Curr. Pain Headache Rep."},{"issue":"8","key":"10.1016\/j.jns.2021.117505_bb0145","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/17512433.2019.1635452","article-title":"Fremanezumab for the preventive treatment of migraine in adults","volume":"12","author":"Lionetto","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"S3","key":"10.1016\/j.jns.2021.117505_bb0150","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/head.13417","article-title":"Anti-calcitonin gene-related peptide (CGRP) therapies: update on a previous review after the American headache society 60th scientific meeting, San Francisco, June 2018","volume":"58","author":"Tepper","year":"2018","journal-title":"Headache: J. Head Face Pain."},{"key":"10.1016\/j.jns.2021.117505_bb0155","series-title":"CADTH Issues in Emerging Health Technologies [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health","article-title":"Monoclonal antibodies to prevent migraine headaches","author":"Ibekwe","year":"2016"},{"issue":"4","key":"10.1016\/j.jns.2021.117505_bb0160","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/head.13501","article-title":"The impact of spinal manipulation on migraine pain and disability: a systematic review and meta-analysis","volume":"59","author":"Rist","year":"2019","journal-title":"Headache: J. Head Face Pain."},{"issue":"1","key":"10.1016\/j.jns.2021.117505_bb0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s10194-016-0703-0","article-title":"Network meta-analysis of migraine disorder treatment by NSAIDs and triptans","volume":"17","author":"Xu","year":"2016","journal-title":"J. Headache Pain."},{"issue":"3","key":"10.1016\/j.jns.2021.117505_bb0170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/WCO.0000000000000808","article-title":"Evolving options for the treatment of cluster headache","volume":"33","author":"Villar-Martinez","year":"2020","journal-title":"Curr. Opin. Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21001994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21001994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:55:41Z","timestamp":1758383741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21001994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":34,"alternative-id":["S0022510X21001994"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117505","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117505"}}